Rare disease drugmakers brace for potential Trump administration price cuts amid GOP push on health‑care fraud

Rare disease drugmakers are watching the Trump administration closely as proposals emerge that could force lower prices for their specialty therapies. The companies are exploring strategies to mitigate the impact of any mandated cuts.

A recent KFF poll shows that while rising out‑of‑pocket costs dominate voters' health concerns, Republican voters are especially focused on cracking down on fraud in government health programs.

At the same time, pharmacy benefit managers are reported to be navigating around state regulations, adding another layer of complexity for drugmakers and policymakers alike.